-+ 0.00%
-+ 0.00%
-+ 0.00%

AARD Stock News: Robbins LLP Reminds Aardvark Therapeutics, Inc. Stockholders to Contact the Firm Before the October 13, 2026 Lead Plaintiff Deadline

Barchart·09/30/2026 16:58:00
Listen to the news

SAN DIEGO, Sept. 30, 2026 /PRNewswire/ -- Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities who purchased or otherwise acquired Aardvark Therapeutics, Inc. (NASDAQ: AARD) (a) common stock pursuant to the Company's February 13, 2025 initial public offering ("IPO") and/or (b) securities between February 13, 2025 and May 14, 2026 (the "Class Period"). Aardvark is a clinical-stage biopharmaceutical company that focuses on developing small-molecule therapies designed to inhibit hunger and treat metabolic diseases such as Prader-Willi Syndrome ("PWS"), a neurodevelopmental disorder condition that presents hyperphagia, or a feeling of extreme, insatiable hunger.

Read more at prnewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.